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We examined the effect of three types of prenatal supplements containing different
amounts of iron on haemoglobin (Hb) and iron status (zinc protoporphyrin [ZPP] and
soluble transferrin receptor [sTfR]) in late pregnancy among 1,379 women in rural
Malawi. Participants were recruited at ≤20 gestational weeks (gw) and randomly
assigned to consume daily (1) 60‐mg iron and folic acid (IFA); (2) 20‐mg iron plus
17 micronutrients in a capsule (MMN); or (3) lipid‐based nutrient supplement (LNS;
118 kcal) with 20‐mg iron plus 21 micronutrients, protein, and fat. We analysed
differences between intervention groups in mean Hb, ZPP, and sTfR at 36 gw, and the
proportionwith anaemia (Hb < 100 g L−1) and iron deficiency (ZPP > 60 μmolmol−1 haem
or sTfR > 6 mg L−1) at 36 gw. Women in the IFA group had higher Hb at 36 gw than
women in the LNS group (P = 0.030) and higher iron status (lower ZPP and sTfR) than
women in both the LNS (P < 0.001 for both ZPP and sTfR) and MMN (P = 0.025 and
P = 0.046) groups. Results for anaemia and iron deficiency showed similar trends. Further
research is needed to elucidate the appropriate amount of iron to improve Hb and iron
status, while improving birth outcomes.
KEYWORDS
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Anaemia during pregnancy is a risk factor for preterm birth and low
birthweight, in addition to maternal and infant death (Allen, 2000;- - - - - - - - - - - - - - - - - - - - - - - - - - -
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rrin receptor; ZPP, zincNew & Wirth, 2015). The global prevalence of anaemia among
pregnant women is estimated to be 19.2% (World Health Organization
[WHO], 2015), whereas in sub‐Saharan Africa, an estimated 57% of
pregnant women are anaemic (Soares Magalhaes & Clements, 2011).
Although there are multiple etiologies for anaemia, including micronu-
trient deficiencies, haemoglobinopathies, and acute and chronic
infections, one of the most prevalent causes of anaemia is iron
deficiency (Crawley, 2004).- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
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Key messages
• Pregnant Malawian women who consumed 60‐mg iron
per day in an iron–folic acid supplement from ≤20
gestational weeks had higher Hb and markers of iron
status at 36 gestational weeks than did women who
consumed 20 mg day−1 as a lipid‐based nutrient
supplement or a multiple micronutrient capsule.
• There were no differences in prevalence of anaemia or
iron deficiency anaemia between the three groups at
36 gestational weeks.
• Further research is needed to elucidate the optimal dose
of supplemental iron during pregnancy in this
population.
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bs_bs_bannerIron supplementation during pregnancy is helpful in preventing
iron deficiency. A recent Cochrane review reported a 70% reduction
in maternal anaemia and a 57% reduction in iron deficiency at term
among women who received preventive iron supplementation during
pregnancy (Pena‐Rosas, De‐Regil, Garcia‐Casal, & Dowswell, 2015).
However, the optimal dose of iron is still not known. The WHO rec-
ommends 30–60 mg of elemental iron per day, with a preferred daily
dose of 60 mg day−1 in areas where anaemia among pregnant women
is a severe public health problem (WHO, 2012). The UNICEF/WHO/
UNU international multiple micronutrient preparation for pregnant
and lactating women provides the Recommended Dietary Allowance
(RDA) of 15 vitamins and minerals, including 30 mg of iron. A daily
supplement with 30 mg (rather than 60 mg) of iron was chosen for
multiple reasons (lower side effects with a daily dose of 30 vs.
60 mg; other vitamins in the supplement enhance iron absorption;
the need for higher doses of zinc with higher doses of iron would fur-
ther exacerbate side effects; and the ability to use higher doses of iron
in conjunction with the supplement for cases of more severe anaemia;
Adu‐Afarwuah et al., 2016; UNICEF/UNU/WHO, 1999). However,
even supplementation with only 30 mg of iron has been associated
with side effects (Pena‐Rosas, De‐Regil, Dowswell, & Viteri, 2012).
The International Lipid‐based Nutrient Supplement (iLiNS) Project
(www.ilins.org) was designed to study the impact on maternal and
infant health of supplementation with a small‐quantity lipid‐based
nutrient supplement (SQ‐LNS) provided to pregnant and lactating
women and their children from 6 to 18 months of age. LNS differ from
micronutrient supplements or fortificants because they are food prod-
ucts and contain energy, protein, and essential fatty acids, as well as a
wider range of micronutrients than most micronutrient supplements
or fortificants, including several macrominerals required for growth.
The iron content per daily dose of 20 g of the SQ‐LNS used in this
study was set at 20 mg, as described previously (Arimond et al.,
2015), which is lower than the 30 mg in the UNICEF/WHO/UNU
international multiple micronutrient preparation supplement. Supple-
mentation with 20 mg day−1 had been shown to be adequate to
prevent iron deficiency anaemia during pregnancy (even among
women who were anaemic at entry into prenatal care), while not caus-
ing gastrointestinal upset commonly associated with higher doses of
iron (Milman, Byg, Bergholt, Eriksen, & Hvas, 2006; Zhou, Gibson,
Crowther, & Makrides, 2009). The RDA for iron during pregnancy is
27 mg day−1, which drops to 9 mg day−1 during lactation (Food and
Nutrition Board Institute of Medicine, 2002). Pregnant women in the
Mangochi District in Malawi consume an estimated 16–18 mg of iron
per day (Hjertholm et al., 2018; Ndekha, 1998). Although this is higher
than the median intake among pregnant women in the United States
(approximately 15 mg day−1; Food and Nutrition Board Institute of
Medicine, 2002), it is still well below the RDA. We estimated that con-
suming a supplement with 20 mg day−1, combined with iron from the
diet, would provide sufficient iron during pregnancy (without greatly
exceeding the RDA during lactation), based on data indicating that iron
absorption in the third trimester of pregnancy is high—25–66% when
a modest dose of iron (6–18 mg) is consumed daily with food (Barrett,
Whittaker, Williams, & Lind, 1994; Whittaker, Barrett, & Lind, 2001).
Women in the second trimester need approximately 4–5 mg day−1
of absorbed iron, which increases to 5–6 mg day−1 in the thirdtrimester (Food and Nutrition Board Institute of Medicine, 2002).
Assuming at least 10% absorption of iron from food (the estimated
bioavailability from vegetarian diets; Food and Nutrition Board Insti-
tute of Medicine, 2002), we calculated that at least 1.5‐mg iron per
day would be absorbed from the diet. Assuming 25% of the iron in
LNS is absorbed, 20 mg of iron in LNS would provide at least
5 mg day−1 of absorbed iron, which together with at least 1.5 mg of
dietary iron would be sufficient to meet the needs in late pregnancy
when demand is highest.
The primary aim of the iLiNS Project was to examine the effect of
SQ‐LNS on birth outcomes and infant growth. Additionally, we have
examined a wide range of secondary outcomes among pregnant women
and infants, including haemoglobin (Hb) and iron status among pregnant
Ghanaian women (Adu‐Afarwuah et al., 2016). In the present study, we
examine the effect of three iron‐containing supplements (iron and folic
acid [IFA], multiple micronutrient [MMN] capsule, and SQ‐LNS) on Hb
and markers of iron status (zinc protoporphyrin [ZPP] and soluble trans-
ferrin receptor [sTfR]) among pregnant Malawian women.2 | METHODS
The iLiNS Project DYAD Malawi trial was a randomized, controlled,
outcome assessor‐blinded supplementation trial of mother–child
dyads in the Mangochi District of rural Malawi (iLiNS‐DYAD‐M). The
study has been described in detail elsewhere (Ashorn et al., 2015).
The primary study focused on the effect of intervention on newborn
outcomes and child growth. We have published or plan to publish
various articles on other nutrient biomarkers and other outcomes.
The focus of the current study is iron deficiency and anaemia. Briefly,
study nurses explained the study to women who came to one of the
study clinics for antenatal care and who were greater than 15 years
of age and no more than 20 gestational weeks (gw). Interested women
signed or thumbprinted an informed consent and were enrolled in the
study if eligible. Women who had chronic medical conditions, preg-
nancy complications at enrolment (moderate to severe oedema, blood
Hb concentration <50 g L−1, systolic blood pressure >160 mmHg, or
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DYAD, or concurrent enrolment in another clinical trial were excluded.
We enrolled 1,391 women.
Women were randomly assigned to one of three intervention
groups in blocks of nine by selecting an opaque envelope that
contained one of nine letters. Each intervention group had three
letters that corresponded to it. Women in the IFA group were
instructed to consume each day from enrolment until delivery a cap-
sule that contained 60 mg of iron and 400 μg of folic acid and from
delivery to 6 months post‐partum a placebo capsule. IFA during preg-
nancy (but not post‐partum) is considered the standard of care in
Malawi. Women in the MMN group were instructed to consume each
day from enrolment to 6 months post‐partum a capsule that contained
20 mg of iron, in addition to folic acid and 16 additional micronutrients
(Table S1). The IFA/placebo and MMN capsules were identical in
appearance. Women in the SQ‐LNS group were instructed to con-
sume each day from enrolment to 6 months post‐partum a 20‐g dose
of LNS that contained the same 18 micronutrients as the MMN cap-
sule, as well as four additional minerals, protein, and fat, and also pro-
vided 118 kcal of energy. Fifteen supplement doses were delivered by
study staff every 14 days. Women in the IFA and MMN groups were
instructed to consume the capsules with water after a meal, whereas
those in the LNS group were instructed to mix one sachet of LNS with
a small amount of food consumed as one dose in the morning. The
LNS used in this study was deemed acceptable in the study catchment
area (Phuka et al., 2011). On the same days that supplements were
delivered, any remaining supplements from the previous delivery were
counted and collected. The capsules were manufactured by DSM
Nutritional Products South Africa (Pty) Ltd (Isando, South Africa). The
LNS was produced and packed by Nutriset S.A.S. (Malaunay, France).
The capsules and LNS were stored in a dark environment at 20–40°C.
Field workers who delivered supplements were the only study staff
who knewwhich women received LNS (but they did not know the differ-
ence between MMN and IFA), and participants were instructed not to
disclose information about their supplements to anyone other than the
field workers. Besides fieldworkers who delivered supplements, all study
staff, laboratory staff, and statisticians were blinded to group allocation.
A statistician not involved in iLiNS‐DYAD‐Mmaintained the intervention
code, whichwas stored sealed and not broken until all laboratory and sta-
tistical analyses were performed.
At the enrolment visit, sociodemographic information was col-
lected by trained study staff. Trained anthropometrists measured the
participants' weight and height in triplicate using high‐quality scales
(SECA 874 flat scale, Seca GmbH & Co., Hamburg, Germany) and
stadiometers (Harpenden stadiometer, Holtain Limited, Crosswell,
Crymych, UK). Peripheral malaria parasitaemia was measured with a
rapid test kit (Clearview Malarial Combo, Alere, South Africa), and HIV
was analysed using a whole‐blood antibody rapid test (Alere Determine
HIV‐1/2, Alere, South Africa) and using another whole‐blood antibody
rapid test (Uni‐Gold HIV, Trinity Biotech plc, Bray, Ireland).
At the enrolment and 36 gw planned study visits, clinic nurses col-
lected blood from the antecubital vein into a 7.5‐ml trace mineral‐free
polypropylene syringe (Sarstedt Monovette, NH4‐heparin, Sarstedt
Inc., Newton, NC, USA). The blood tube was immediately inverted
10 times to mix the heparin anticoagulant with the blood to preventclotting. A small aliquot of the whole blood was pipetted out and used
to analyse Hb on the Hemocue 201+ system (Hemocue, Brea, CA,
USA). The tube containing the remaining whole blood was then placed
in an insulated cooler with ice packs until processing. Trained lab staff
then aliquoted whole blood into microcuvettes and washed the red
cells 3 times. The washed red cells were used for ZPP analysis (Aviv
hematofluorometer, Aviv Biomedical Inc., Lakewood, NJ, USA).
Trained lab staff then centrifuged the whole blood at 3,000 RPM for
15 min and separated plasma into storage cryovials. The storage vials
were placed upright in freezer boxes in a −20°C freezer for temporary
storage at the satellite clinics. Within 48 hr, drivers transported the
plasma to the main laboratory for long‐term storage at −80°C.
Plasma was shipped to UCD on dry ice (World Courier) for analy-
sis. We analysed sTfR from those samples by immunoturbidimetry on
the Cobas Integra 400 system autoanalyser (F. Hoffmann‐La Roche
Ltd., Basel, Switzerland). We analysed all the samples in singlet, except
for 5%, which we randomly selected to be analysed in duplicate. None
of those samples had a coefficient of variation greater than 5%.
ZPP and sTfR are commonly used markers of iron status. There is
an inverse correlation between iron status and ZPP, as during iron
deficiency, zinc, instead of iron, is incorporated into protoporphyrin
IX, resulting in the formation of ZPP (Braun, 1999). The concentration
of sTfR is also inversely proportional to total body iron status, as cells
upregulateTfR when iron is needed in cells. SolubleTfR is proportional
to the concentration of cellular TfR (Beguin, 2003). Ferritin is a com-
monly used marker of iron status. However, we did not analyse serum
or plasma ferritin because we expected a high prevalence of inflamma-
tion in the study population, which complicates the interpretation of
ferritin measurements.
Anaemia was defined as Hb <100 g L−1, which has been
suggested as an appropriate cut‐off for pregnant women of African
descent (Cao & O'Brien, 2013; Chang, O'Brien, Nathanson, Mancini,
& Witter, 2003; Johnson‐Spear & Yip, 1994). In exploratory analyses,
we also examined differences between groups in proportion of
women with anaemia and iron deficiency anemia (IDA) using an Hb
cut‐off of 110 g L−1 (WHO, 2011). High Hb was defined as >130 g L−1
(Pena‐Rosas et al., 2015). Iron deficiency was defined as ZPP
>60 μmol mol−1 haem (Walsh et al., 2011) or sTfR >6.0 mg L−1. An sTfR
cut‐off of 8.5 mg L−1 has been used previously when analysing sTfR by
the enzyme‐linked immunosorbent assay (ELISA) method (Carriaga,
Skikne, Finley, Cutler, & Cook, 1991; Rusia et al., 1999; Vandevijvere,
Amsalkhir, Van Oyen, Egli, & Moreno‐Reyes, 2013). However, Pfeiffer
et al. (2007) compared the ELISA and autoanalyser methods and found
that the autoanalyser gives sTfR estimates approximately 30% lower than
the ELISA method. Therefore, we decreased the 8.5 mg L−1 cut‐off by
approximately 30%, to 6.0 mg L−1. IDA was defined as Hb <100 g L−1
and either ZPP >60 μmol mol−1 haem or sTfR >6.0 mg L−1.
The trial was performed according to Good Clinical Practice
guidelines and the ethical standards of the Helsinki Declaration. The
protocol was approved by the College of Medicine Research and
Ethics Committee, University of Malawi, Institutional Review Board
at UC Davis, and the Ethics Committee of Pirkanmaa Hospital District,
Finland. Key details of the protocol were published at the clinical trial
registry of the National Library of Medicine, Bethesda, MD, USA
(http://www.clinicaltrials.gov/, trial identification NCT01239693).
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Details of the sample size calculation are described in detail elsewhere
(Ashorn et al., 2015). Briefly, assuming an effect size of 0.3 (difference
between groups, divided by the pooled SD) for each continuous
outcome, assuming 80% power and a two‐sided Type I error rate of
5% would require 216 participants per group, for a total of 648 partic-
ipants. Allowing for up to 25% loss to follow‐up, we would have
needed to recruit 864 subjects. A secondary aim of the primary study
was to study the interaction between the maternal intervention and
several potential effect modifiers, which required that we increase
the sample size. The final sample size of 370 per group provided the
study with 80% power to detect main effects of >0.23 SD.
We performed statistical analysis with the SAS version 9.3 software
package (SAS Institute Inc., Cary, NC, USA). We conducted the statistical
analysis according to the analysis plan written and published before the
intervention code was opened (www.ilins.org). We based the analysis
on the principle of modified intention to treat. That is, we included in
the analyses all participants who were randomized, except that those
with missing data on an outcome variable were excluded from the analy-
ses of that outcome. Two participants whose group allocation was incor-
rectly transcribed and assigned during enrolment were included in the
group corresponding to the actual intervention they received throughout
the trial. Outcome variables were inspected for conformance to normal
distribution and were transformed where necessary. Soluble TfR, ZPP,
C‐reactive protein (CRP), and α‐1‐acid glycoprotein (AGP) were
log‐transformed before analyses were performed.
We analysed differences between those included and excluded
from the current analysis by Student's t test (comparison of means)
or Fisher's exact test (comparison of proportions). We analysed the
differences between groups in mean Hb, ZPP, and sTfR at 36 gw, with
the main effect being intervention group with and without controlling
for baseline status of each variable and chosen covariates. Unadjusted
analyses were performed using analysis of variance models, whereas
analysis of covariance (ANCOVA) was used for unadjusted models. We
then performed pairwise comparisons with a Tukey–Kramer adjustment.
We compared the differences between groups in the proportion ofwomen
who had lowor highHb, high ZPP or sTfR, or who had IDA (i.e., lowHb and
either high ZPP or sTfR) at either the baseline or the 36 gw visit by log‐
Poisson regression. We examined values at 36 gw with and without con-
trolling for the baseline status for each variable and chosen covariates.
The covariates in the ANCOVA and log‐Poisson regression
models were included based on whether these variables (a) have been
shown in prior work to influence the outcome and (b) were associated
(P < 0.10) with the outcome in bivariate analyses. The following
baseline variables were selected a priori and were examined as poten-
tial covariates: maternal body mass index (BMI) at enrolment, malaria
status, HIV status, primiparity, maternal educational achievement, site
at enrolment, season of enrolment, maternal Hb (for ZPP and sTfR
analyses), and ZPP and sTfR (for Hb analyses).
To examine effect modification, variables were selected a priori
based on their expected associations with Hb, ZPP, and sTfR. Two‐way
interactions between group assignment and Hb, ZPP, sTfR, CRP, AGP,
and BMI at enrolment; maternal educational achievement, HIV status,
malaria status at enrolment, and season of and site at enrolment wereincluded separately in the ANCOVA models (for continuous outcomes)
or logistic regression (for bivariate outcomes) for Hb, ZPP, and sTfR at
36 gw. Significant interactions (P < 0.05) were further examined by
stratifying participants into high or low categories for continuous effect
modifiers or presence or absence of a predictor for bivariate effect
modifiers, in order to understand the nature of the effect modification.
Because of the known effect of inflammation on Hb (Weiss &
Goodnough, 2005), we conducted a sensitivity analysis to compare
the groupwise differences in mean Hb at 36 gw (by ANCOVA) and
proportion of women who were anaemic at 36 gw (by log‐Poisson
regression) after excluding cases with elevated CRP or AGP at
36 gw. Both models controlled for baseline Hb, CRP, and AGP.
Elevated CRP was defined as CRP >5 g L−1, and elevated AGP was
defined as AGP >1 mg L−1 (Thurnham et al., 2010).3 | RESULTS
Women were enrolled at the four antenatal clinics between February
2011 and August 2012. Of the 9,310 women approached by iLiNS
Malawi team members, 1,391 were successfully enrolled and random-
ized to one of the three intervention groups, with a mean gestational
age at enrolment of 16.8 weeks (Figure 1). Twelve of those enrolled
carried twins and were excluded from the analyses. Of the remaining
1,379 included in the analyses, we analysed Hb at enrolment from
1,377 (99.9%), ZPP from 1,325 (96.1%), and sTfR from 1,371
(99.4%). At the 36 gw visit, we analysed Hb from 1,040 (75.4% of
the original 1,379 women who completed the enrolment visit), ZPP
from 1,008 (73.1%), and sTfR from 1,067 (77.4%). There were 352,
363, and 352 participants in the IFA, MMN, and LNS groups, respec-
tively, who were included in the analyses at 36 gw. There were no
differences between intervention groups in the proportion of women
from whom Hb, ZPP, and sTfR at 36 gw were not available (P > 0.8 for
all). There were no differences between groups in the mean (SD)
percentage of days supplements were consumed (IFA, 84.2 [16.6];
MMN, 83.4 [18.1]; LNS, 85.6 [16.9]; P = 0.170), severe adverse events
(IFA, 9.1%; MMN, 9.7%; LNS, 11.9%; P = 0.353), or preterm delivery
(IFA, 11.3%; MMN, 9.5%; LNS, 9.1%; P = 0.528).
The baseline characteristics of the participants included in the
current analyses at 36 gw are shown in Table 1. Compared with those
included in the current analyses at 36 gw, those not included in the
current analyses were on average younger and of higher socio‐
economic status (P < 0.001 for both) and had a higher proportion of
primiparity and anaemia (P < 0.001 for both; Table S2).
At enrolment, the mean (SD) Hb level of all participants included in
these analyses was 111.5 (16.3) g L−1. The prevalence of anaemia
(Hb <100 g L−1) was 20.8%, whereas 11.1% had high Hb (>130 g L−1).
The mean (SD) ZPP at enrolment was 54.5 (41.6) μmol mol−1 haem, with
24.5% of participants having high ZPP (>60 μmol mol−1 haem). The mean
(SD) sTfR was 4.8 (2.7) mg L−1, with 19.7% having high sTfR (>6 mg L−1).
At 36 gw, the mean (SD) Hb was 110.8 (15.2) g L−1, 20.4% of
women were anaemic, and 8.5% had high Hb. The mean (SD) ZPP at
36 gw was 60.2 (40.9) μmol mol−1 haem, with 34.0% of participants
having high ZPP. The mean (SD) sTfR was 5.6 (3.0) mg L−1, with
33.5% of participants having high sTfR.
FIGURE 1 Schematic representation of
recruitment, enrolment, and follow‐up of
Malawian women who participated in the
iLiNS Project. IFA: iron–folic acid; MMN:
multiple micronutrient; Hb: haemoglobin;
ZPP: zinc protoporphyrin; sTfR: soluble
transferrin receptor
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and sTfR between the intervention groups at 36 gw. Results were
generally similar whether or not they were adjusted for the baseline
value of the outcome variable, and further adjustment for other
covariates did not change the findings. After adjusting for baseline
Hb, the mean Hb at 36 gw in the IFA group was significantly greater
than in the LNS group (P = 0.030) and tended to be greater than in
the MMN group (P = 0.058). Adjusting for baseline ZPP, mean ZPP
at 36 gw was lower in the IFA group than in both the LNS group
(P < 0.001) and the MMN group (P = 0.025). Similarly, mean sTfR
at 36 gw was lower in the IFA group compared with either the
LNS (P < 0.001) or MMN group (P = 0.046) in models adjusted for
baseline sTfR.Table 3 shows that there were no differences in the prevalence of
anaemia, high Hb, high sTfR, or IDA (using a cut‐off of 100 g L−1)
between groups after adjusting for the baseline status. There were
differences between intervention groups in prevalence of iron
deficiency when defined by high ZPP but not when defined by high
sTfR. Specifically, there was a greater risk of high ZPP among women
in the LNS group compared with both the IFA (RR [95% CI]: 1.86
[1.22, 2.83]) and MMN (RR: 1.69 [1.12, 2.56]) groups after adjusting
for baseline ZPP.
When using a cut‐off of 110 g L−1 to define anaemia and IDA,
there continued to be no differences in the prevalence of anaemia
between intervention groups (global P = 0.158; data not shown), but
the risks of IDA among women in the LNS and MMN groups were
TABLE 1 Baseline characteristics of pregnant Malawian women included in analyses at 36 gestational weeks, by intervention group
Characteristic IFA MMN LNS
Number of participants 352 363 352
Mean (SD) age (years) 25.1 (5.9) 25.4 (6.1) 25.3 (6.3)
Mean (SD) gestational age at enrolment (weeks) 16.8 (2.1) 16.8 (2.1) 16.9 (2.2)
Mean (SD) education (completed years) 4.0 (3.4) 4.0 (3.4) 4.1 (3.5)
Mean (SD) socio‐economic score −0.06 (1.0) −0.04 (0.9) −0.02 (1.0)
Proportion of nulliparous women 19.4% 19.1% 20.7%
Mean (SD) body mass index (BMI; kg m−2) 22.1 (2.6) 22.2 (3.0) 22.1 (2.8)
Proportion of women with a low BMI (<18.5 kg m−2) 5.4% 5.0% 6.6%
Proportion of anaemic women (Hb <100 g L−1) 18.2% 18.0% 19.6%
Proportion of anaemic women (Hb <110 g L−1) 45.0% 43.8% 43.4%
Proportion of women with a positive HIV test 14.7% 10.3% 13.1%
Proportion with a positive malaria test (RDT) 21.3% 24.0% 23.1%
Note. Hb: haemoglobin; IFA: iron–folic acid; MMN: multiple micronutrients; LNS: lipid‐based nutrient supplement.
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1.85] and 1.31 [1.02, 1.70], respectively; Table 3).
There were no significant interactions (P < 0.05) between group
assignment and potential effect modifiers when the outcome was
mean ZPP or sTfR or proportion with elevated ZPP or sTfR at 36 gw.
There were significant interactions between group assignment and
baseline Hb or sTfR when the outcome was mean Hb or the proportion
of women with high Hb at 36 gw (Table 4). However, in stratified anal-
ysis, there were no differences in mean Hb or probability of elevated
Hb between groups among women who were or were not anaemic
at enrolment. There were no differences in mean Hb among those
without elevated sTfR at enrolment, but among those with elevated
sTfR at enrolment, Hb was greater at 36 gw in the IFA group compared
with both the MMN and LNS groups (P = 0.020 and P = 0.005, respec-
tively). There were no differences in probability of elevated Hb among
those with or without high sTfR at enrolment. There was also a signif-
icant interaction between group assignment and presence of malaria
infection with regard to the proportion of women with low Hb at
36 gw. Specifically, among those with malaria at enrolment, the prob-
ability of low Hb at 36 gw was lower in the IFA and MMN groups than
in the LNS group (P = 0.028 and P = 0.014, respectively), but there
were no differences among women without malaria at enrolment.
We also examined differences in mean Hb and proportions of
women with low or high Hb among women without inflammation
(CRP <5 mg L−1 and AGP <1 g L−1). Of the 1,026 women from whom
Hb, CRP, and AGP data were available at 36 gw, 318 had inflammation
and were excluded. We found no differences between intervention
groups in mean Hb at 36 gw (P = 0.112; Table 2) or prevalence of
anaemia (P = 0.104; Table 3) after adjusting for baseline Hb, CRP,
and AGP. There were no differences between the intervention groups
in the proportion of women with elevated Hb (P = 0.358) after exclud-
ing women with inflammation in adjusted models.4 | DISCUSSION
Among pregnant Malawian women enrolled in the iLiNS‐DYAD study,
those who were provided with IFA (60 mg of iron per day) fromenrolment (≤20 gw) to 36 gw had higher Hb and markers of iron sta-
tus at 36 gw compared with those provided with LNS or MMN (20 mg
of iron per day). Furthermore, the prevalence of anaemia tended to be
lower in the IFA group compared with the MMN and LNS groups,
which corresponds with greater iron deficiency (high ZPP) in the
LNS and MMN groups compared with the IFA group, although there
were no apparent differences in high sTfR.
These results are similar to those of the sister iLiNS‐DYAD trial in
Ghana that had the same study design and interventions as the study
in Malawi (Adu‐Afarwuah et al., 2016). In both sites, Hb and iron sta-
tus were higher among those provided with IFA, compared with LNS
and MMN. However, in Ghana, the prevalence of anaemia (Hb
<100 g L−1) decreased during pregnancy and was quite low (2–8%)
by 36 gw, whereas in Malawi, the prevalence of anaemia was similar
at enrolment and 36 gw and was higher at 36 gw (~20% at 36 gw)
than in Ghana. At the same time, the prevalence of high Hb increased
during pregnancy in Ghana, yet decreased in Malawi. There were a
number of differences between the Ghana and Malawi populations
that may have contributed to the differences in prevalence of low
and high Hb. At enrolment, the Ghanaian women had higher Hb, lower
prevalence of anaemia and iron deficiency, lower prevalence of
malaria, younger age, higher BMI, higher education level, and higher
socio‐economic status, and were more likely to be nulliparous.
One obvious explanation for the higher mean Hb and iron status
in the IFA group compared with the LNS and MMN groups at 36 gw
is that the dose of iron in the IFA was 3 times greater than in the
MMN or LNS. Other studies in a variety of populations have shown
no differences in Hb or iron status between women who consumed
30 mg of iron in MMN compared with those who consumed 60 mg
of iron together with folic acid (Allen, Peerson, & Maternal Micronutri-
ent Supplementation Study, 2009; Mei et al., 2014; Roberfroid et al.,
2011). It is possible that the extra 10 mg of iron (30 mg in the latter
studies vs. 20 mg in the LNS and MMN used in the current study)
accounts for the difference in results. In Australia, Zhou et al. (2009)
found that a 20‐mg daily dose of iron was adequate to prevent iron
deficiency during pregnancy, but in Denmark, pregnant women who
consumed 20 mg of iron per day had a higher prevalence of iron defi-
ciency and IDA compared with those who consumed 40 mg day−1
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TABLE 4 Significant interactions with effect of intervention on mean Hb and proportions with low or high Hb among Malawian women at 36
gestational weeks, by baseline level of the effect modifiers
Outcome Effect modifier
Estimated least squares mean [95% CI] or estimated probability of outcomea P value
for the
interaction
P value
for the difference
between groupsIFA MMN LNS
Hb at 36 gw
(g L−1)
Anaemic at enrolment 0.026
No 115.2 [113.5, 116.9] 112.6 [111.0, 114.3] 113.0 [111.3, 114.6] 0.062
Yes 104.7 [101.2, 108.3] 102.5 [99.1, 105.9] 100.9 [97.5, 104.3] 0.297
High sTfR at enrolment 0.003
No 113.7 [112.0, 115.4] 112.1 [110.3, 113.8] 112.2 [110.5, 113.9] 0.325
Yes 112.4 [108.5, 116.3]a 105.4 [102.0, 108.8]b 103.9 [100.2, 107.6]b 0.004
Low Hb
(<100 g L−1)
Malaria at enrolment 0.023
No 0.17 [0.13, 0.22] 0.23 [0.18, 0.28] 0.20 [0.15, 0.25] 0.290
Yes 0.15 [0.08, 0.25]b 0.13 [0.08, 2.22]b 0.32 [0.23, 0.43]a 0.005
High Hb
(>130 g L−1)
Anaemic at enrolment 0.024
No 0.11 [0.07, 0.15] 0.08 [0.05, 0.11] 0.09 [0.06, 0.13] 0.444
Yes 0.04 [0.01, 0.13] 0.01 [<0.01, 0.09] <0.01 [<0.01, >0.99] 0.599
High sTfR at enrolment 0.019
No 0.09 [0.06, 0.13] 0.06 [0.04, 0.10] 0.05 [0.03, 0.09] 0.101
Yes 0.10 [0.05, 0.21] 0.07 [0.03, 0.15] 0.06 [0.02, 0.14] 0.101
Note. The models for Hb at 36 gw were adjusted for log‐AGP at enrolment, the season when enrolled, and site of enrolment. The models for low Hb were
adjusted for log‐ZPP at enrolment. The models for high Hb were adjusted for the season when enrolled. AGP: α‐1‐acid glycoprotein; Hb: haemoglobin; IFA:
iron–folic acid; LNS: lipid‐based nutrient supplement; MMN: multiple micronutrients; sTfR: soluble transferrin receptor; ZPP: zinc protoporphyrin. Sub-
scripts with nonmatching letters are significantly different (P < 0.05).
aEstimated least squares mean (95% confidence interval) Hb at 36 gw, or estimated probability of low or high Hb among those with and without anaemia,
elevated sTfR, or malaria. Analyses are based on ANCOVA (SAS PROC GLM, with SLICE option) for continuous outcomes or logistic regression (SAS PROC
GLIMMIX, with SLICE option) for binary outcomes.
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bs_bs_banner(Milman et al., 2005), which is in line with our findings. Given the high
intake of plant‐based foods in Malawi (Ndekha, 1998), it is possible
that 20 mg day−1 is not an adequate supplement for this population,
as the phytate in certain plant‐based foods inhibits iron absorption.
There was a greater prevalence of IDA in the LNS and MMN
groups compared with the IFA group when a cut‐off of 110 g L−1
was used instead of 100 g L−1. This could signify that a higher cut‐
off is better able to detect IDA among women who have moderate
IDA. Or it could falsely diagnose healthy women as having IDA. Our
original plan was to use 100 g L−1 as the cut‐off, as has been sug-
gested by WHO and International Nutritional Anemia Consultative
Group for adequate sensitivity and specificity in screening for IDA
among pregnant women of African descent (Nestel & INACG Steering
Committee, 2002; WHO, 2007; WHO/UNICEF/UNU, 2001). Without
analysis of functional outcomes associated with IDA, the best cut‐off
to use in this population is not known.
There were no apparent differences between the LNS and MMN
groups in mean values of Hb or markers of iron status, but there was a
higher prevalence of elevated ZPP (but not sTfR) at 36 gw in the LNS
compared with the MMN group. Some substances in the LNS but not
present in the MMN may have inhibited iron absorption from the LNS,
such as calcium (280 mg per serving) and phytic acid (from peanuts). In
nonpregnant, multiparous Chilean women, average (±1 SD) absorption
of iron from iron sulfate alone was 25.0% (11.9% to 52.2%), compared
with 13.2% (7.1% to 24.6%) when consumed with calcium and phytic
acid (Jaramillo et al., 2015).
Although there was no apparent main effect of intervention group
on prevalence of anaemia at 36 gw, there were interaction effects that
were significant. Among women who were iron deficient at enrolment
(as indicated by high sTfR), Hb was higher at 36 gw among women in
the IFA group compared with both the LNS and MMN groups. Thissuggests that iron deficient women may benefit more from the higher
dose of iron in the IFA supplements. Among those with malaria at
enrolment, the probability of anaemia at 36 gw was greater in the
LNS group compared with either the IFA or MMN group. Although
this may be a spurious finding, it is possible that malaria‐induced
inflammation inhibited iron absorption, which was already potentially
an issue for the LNS group.
Strengths of the study include random allocation of participants,
blinding of group assignment among staff involved in data collection,
laboratory analyses, and statistical analyses, and rigorous quality
control during sample collection and laboratory analysis. Given the dif-
ference in participant characteristics between those who were lost to
follow‐up and completed follow‐up, these study findings may not be
generalizable to all individuals in the study catchment area. However,
there were no differences between intervention groups in the propor-
tion lost to follow‐up that may have altered the interpretation of the
effect of intervention on Hb and iron status. Because we excluded
women with Hb <50 g L−1, the results may also not be generalizable
to women with severe anaemia. Another limitation of the study is that
we relied on participant reporting of supplement consumption rather
than direct observation. We were also limited by the inability to blind
study staff and participants from knowing who was in the LNS group.
However, field workers did not know the difference between MMN
and IFA capsules, and all other study staff, laboratory staff, and statis-
ticians were blinded to group allocation until after all laboratory and
statistical analyses were performed. Because of the study design,
women did not start taking supplements until almost 17 gw, on aver-
age. Finally, although we considered various maternal and environmen-
tal factors as potential effect modifiers, we did not have information on
other factors, such as preconceptional iron status or genetic variation
among this population that may have limited iron absorption.
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bs_bs_bannerIn summary, in this population of pregnant Malawian women,
provision of 60 mg of iron in IFA increased mean Hb and markers of
iron status but did not appear to reduce the prevalence of anaemia
in comparison with provision of LNS or MMN containing 20 mg of
iron. Further research is needed to determine (a) why there was no
evidence of a reduced prevalence of anaemia at 36 gw with iron
supplementation in this population and (b) if higher Hb or iron status
later in pregnancy is beneficial with regard to health outcomes of
the mother or infant. With regard to the latter issue, although Hb
status among these women at enrolment (≤20 gw) was positively
associated with birth outcomes (duration of gestation, birthweight,
length‐for‐age z‐score, and head circumference), there were no associ-
ations between Hb at 36 gw and birth size (Dewey & Oaks, 2017). In
similar trials in Ghana and Bangladesh, higher iron status at 36 gw, as
indicated by low sTfR, was associated with lower birthweight, length‐
for‐age z‐score, and head circumference (Dewey & Oaks, 2017), and
evidence from other studies also suggests that elevated Hb and iron
status in later pregnancy are associated with adverse birth outcomes
(Dewey & Oaks, 2017; Steer, Alam, Wadsworth, & Welch, 1995).
Therefore, further evaluation of the optimal dose of supplemental iron
during pregnancy is warranted.
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